PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab

被引：3

作者：

Kaesmann, Lukas ^{[1
,2
,3
]}

Nieto, Alexander ^{[1
]}

Taugner, Julian ^{[1
]}

Manapov, Farkhad ^{[1
,2
,3
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany

[2] German Ctr Lung Res DZL, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany

[3] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany

来源：

TRANSLATIONAL CANCER RESEARCH | 2023年 / 12卷 / 04期

关键词：

NSCLC; stage III; PD-L1; expression; predictive biomarker; durvalumab; CHEMORADIATION;

D O I：

10.21037/tcr-23-52

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：705 / 708

页数：4

共 12 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review [J].

Brody, Robert ;

Zhang, Yiduo ;

Ballas, Marc ;

Siddiqui, Mohd Kashif ;

Gupta, Palvi ;

Barker, Craig ;

Midha, Anita ;

Walker, Jill .

LUNG CANCER, 2017, 112 :200-215

[3] Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study [J].

Desilets, Antoine ;

Blanc-Durand, Felix ;

Lau, Sally ;

Hakozaki, Taiki ;

Kitadai, Rui ;

Malo, Julie ;

Belkaid, Wiam ;

Richard, Corentin ;

Messaoudene, Meriem ;

Cvetkovic, Lena ;

Kazandjian, Suzanne ;

Tehfe, Mustapha ;

Florescu, Marie ;

Jao, Kevin ;

Daaboul, Nathalie ;

Owen, Scott ;

Shieh, Benjamin ;

Agulnik, Jason ;

Cohen, Victor ;

Charbonneau, Chloe ;

Marcoux, Nicolas ;

Blais, Normand ;

Leighl, Natasha B. ;

Bradbury, Penelope A. ;

Liu, Geoffrey ;

Shepherd, Frances A. ;

Bahig, Houda ;

Routy, Bertrand ;

Sacher, Adrian ;

Elkrief, Arielle .

EUROPEAN JOURNAL OF CANCER, 2021, 142 :83-91

[4] Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab [J].

Jazieh, Khalid ;

Gad, Mohamed ;

Saad, Anas ;

Wei, Wei ;

Pennell, Nathan A. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) :3071-3078

[5]

Kartolo A., 2021, Cancer Treat Res Commun., V29, DOI 10.1016/j.ctarc.2021.100496

[6] Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer [J].

Landman, Yosef ;

Jacobi, Oded ;

Kurman, Noga ;

Yariv, Orly ;

Peretz, Idit ;

Rotem, Ofer ;

Dudnik, Elizabeth ;

Zer, Alona ;

Allen, Aaron M. .

ONCOIMMUNOLOGY, 2021, 10 (01)

[7] Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports [J].

Manapov, Farkhad ;

Nieto, Alexander ;

Kaesmann, Lukas ;

Taugner, Julian ;

Kenndoff, Saskia ;

Floersch, Benedikt ;

Guggenberger, Julian ;

Hofstetter, Kerstin ;

Kroeninger, Sophie ;

Lehmann, Janina ;

Kravutske, Helene ;

Pelikan, Carolyn ;

Belka, Claus ;

Eze, Chukwuka .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (03) :187-200

[8] Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab [J].

Offin, Michael ;

Shaverdian, Narek ;

Rimner, Andreas ;

Lobaugh, Stephanie ;

Shepherd, Annemarie F. ;

Simone, Charles B., II ;

Gelblum, Daphna Y. ;

Wu, Abraham J. ;

Lee, Nancy ;

Kris, Mark G. ;

Rudin, Charles M. ;

Zhang, Zhigang ;

Hellmann, Matthew D. ;

Chaft, Jamie E. ;

Gomez, Daniel R. .

RADIOTHERAPY AND ONCOLOGY, 2020, 149 :205-211

[9] Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial [J].

Paz-Ares, L. ;

Spira, A. ;

Raben, D. ;

Planchard, D. ;

Cho, B. C. ;

Ozguroglu, M. ;

Daniel, D. ;

Villegas, A. ;

Vicente, D. ;

Hui, R. ;

Murakami, S. ;

Spigel, D. ;

Senan, S. ;

Langer, C. J. ;

Perez, B. A. ;

Boothman, A-M ;

Broadhurst, H. ;

Wadsworth, C. ;

Dennis, P. A. ;

Antonia, S. J. ;

Faivre-Finn, C. .

ANNALS OF ONCOLOGY, 2020, 31 (06) :798-806

[10] CLINICAL INVESTIGATION Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab [J].

Sankar, Kamya ;

Strohbehn, Garth W. ;

Zhao, Lili ;

Daniel, Victoria ;

Elliott, David ;

Ramnath, Nithya ;

Green, Michael D. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (04) :752-758

← 1 2 →